Addus HomeCare (ADUS) to Post Quarterly Earnings on Monday

Addus HomeCare (NASDAQ:ADUS) is projected to release its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of $1.69 per share and revenue of $376.2420 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 9:00 AM ET.

Addus HomeCare (NASDAQ:ADUS) last released its earnings results on Monday, May 4th. The company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.10. Addus HomeCare had a return on equity of 9.80% and a net margin of 6.89%.The company had revenue of $363.50 million for the quarter, compared to analyst estimates of $366.41 million. During the same period in the prior year, the firm posted $1.42 EPS. Addus HomeCare’s quarterly revenue was up 7.7% on a year-over-year basis. On average, analysts expect Addus HomeCare to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Addus HomeCare Price Performance

Shares of NASDAQ ADUS opened at $114.55 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.83 and a current ratio of 1.83. Addus HomeCare has a 52 week low of $87.95 and a 52 week high of $124.43. The stock has a market capitalization of $2.14 billion, a P/E ratio of 21.17, a PEG ratio of 1.57 and a beta of 0.88. The stock’s fifty day moving average is $99.25 and its 200 day moving average is $101.20.

Insider Buying and Selling at Addus HomeCare

In other Addus HomeCare news, insider Heather Brianne Dixon sold 288 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $93.77, for a total transaction of $27,005.76. Following the sale, the insider owned 44,371 shares of the company’s stock, valued at approximately $4,160,668.67. The trade was a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 788 shares of company stock worth $73,506 over the last quarter. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Addus HomeCare

Hedge funds have recently modified their holdings of the company. Caitlin John LLC bought a new stake in Addus HomeCare during the 4th quarter worth $183,000. Tower Research Capital LLC TRC raised its position in Addus HomeCare by 299.7% in the second quarter. Tower Research Capital LLC TRC now owns 1,563 shares of the company’s stock valued at $180,000 after purchasing an additional 1,172 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Addus HomeCare by 123.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 658 shares of the company’s stock valued at $71,000 after purchasing an additional 363 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Addus HomeCare by 560.0% during the second quarter. EverSource Wealth Advisors LLC now owns 561 shares of the company’s stock valued at $65,000 after purchasing an additional 476 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Addus HomeCare during the second quarter worth about $61,000. Institutional investors and hedge funds own 95.35% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ADUS shares. Weiss Ratings upgraded shares of Addus HomeCare from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 9th. Citizens Jmp restated a “market outperform” rating and issued a $142.00 target price on shares of Addus HomeCare in a research report on Monday, May 18th. Citigroup reaffirmed a “market outperform” rating on shares of Addus HomeCare in a report on Friday. Finally, Barclays lifted their target price on Addus HomeCare from $92.00 to $96.00 and gave the company an “underweight” rating in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $131.50.

Addus HomeCare Company Profile

Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients’ independence and quality of life.

The company’s core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.